Introduction
Angiotensin converting enzyme (ACE) inhibitors are now established as effective anti-hypertensive drugs'' 1 . They also prolong life and delay progression of cardiac failure' 21 . In treatment of hypertension for over 16 years and heart failure for over 10 years, information has accumulated not only on ACE inhibitors as a therapeutic class but also on a number of individual drugs. Many more have been studied in pre-clinical and early clinical research (up to 70 compounds) in addition to the ten agents currently licensed for therapeutic use in the U.K. and Europe' 31 . It is pertinent to ask whether there are any differences between ACE inhibitors? In particular, differences which cannot be attributed to the underlying 'class' effect of inhibition on kininase II or the angiotensin converting enzyme? As will be discussed later, anti-hypertensive efficacy appears to be a 'class' effect associated with ACE inhibition and accompanied by characteristic endocrine changes. Experience of benefits on survival and progression of heart failure have now been reported from several trials with several agents' 21 . Can the effects of ACE inhibitors in heart failure also be considered a 'class' effect? This review addresses these issues by considering what pharmacokinetic or pharmacodynamic differences can be identified between ACE inhibitors and explores whether any of these differences might be clinically relevant to the treatment of hypertension or heart failure.
Pharmacokinetic differences
Examination of differences between drugs of a class can conveniently be divided between those differences dependent on the pharmacokinetic properties (physicochemical characteristics, absorption, disposition, metabolism or elimination) and the pharmacodynamic properties (Table 1) . It is self-evident that different drug molecules by definition will have different physicochemical properties which, in turn, will affect drug disposition. Could any such differences be clinically relevant? Amongst the well-characterized kinetic differences between ACE inhibitors, several have been proposed to be of potential or real clinical relevance.
The presence of a sulphydryl (SH group) in the molecule differs between ACE inhibitors ( , for example, are the active moieties while enalapril 181 and perindopril' 9 ' are examples of drugs given as inactive (or relatively inactive) esters which depend on in vivo metabolism by diesterification to generate the active diacid. There are advantages on occasion in giving prodrugs to improve absorption and bioavailability and to provide an in vivo depot to prolong drug action. However, prodrugs may result in a delay in onset of action and may result in inter-individual differences resulting from genetic polymorphism of drugmetabolizing enzymes and drug interactions. In the case of ACE inhibitors, prodrugs may show a somewhat (4-6 h) delayed peak effect on ACE inhibition and blood pressure fall after oral dosing 18 ' 91 although this is unlikely to be of clinical significance. The esterases affecting activations are ubiquitous and appear promiscuous with regard to substrate so that problems of delayed, limited or absent de-esterification have not been reported' 8 '.
Prodrug activation may be expected to be impaired in patients with hepatic impairment. In practice, the kinetics of perindopril were not significantly changed in patients with liver disease' 10 '. Even amongst the prodrug ACE inhibitors there are differences in that some prodrugs are weakly active and some not active at all. The distribution and tissue penetration of prodrug and active diacid will vary and there is evidence of interactions between prodrug and diacid at the level of ACE enzyme inhibitors. Prodrugs in some cases appear to inhibit the effects of the active diacid' 1 ''. Such interactions could be important determinants of the responses to ACE inhibitors, especially at early times after the first dose when prodrug concentration may be particularly high compared with the active metabolite. Such drug specific interactions could contribute to the profile of response to the first dose of ACE inhibitors'"' (Fig. 1) .
Other kinetic differences which are well characterized are the profile of drug elimination and whether this is predominantly by renal excretion or after hepatic metabolism and inactive metabolites' 12 '. ACE inhibitors show a range of routes of elimination from those which are largely dependent on renal excretion (captopril, enalapril, perindopril) to those with a greater or lesser hepatic component and include examples when both pathways participate (Table 3 ). These differences may be important considerations in choosing an individual drug for an individual patient or group of patients. For example, in treating patients with severe renal failure the clinician can thus choose between using a drug not eliminated by the kidney, where dose adjustment may not be necessary, or a drug which depends on renal excretion, where the dose may need to be reduced depending on the degree of renal failure.
The pharmacokinetic properties of ACE inhibitors will determine plasma concentration profile which in turn determines the duration of effect. The duration of effect is of practical clinical importance as it will influence the choice of optimal dose and dose frequency. Pharmacokinetics of ACE inhibitors are unusual in that the disposition cannot adequately be described by simple one-or two-compartment kinetic models. It appears that slow, tight binding to sites, including plasma and tissue ACE contributes to the late elimination phase' 1314 '. The consequence is that the duration of effect of some ACE inhibitors is longer than would be anticipated from more superficial kinetic overview. Another relevant feature of most ACE inhibitors is the nature of the relationship between plasma concentration and effect in the therapeutic dose range. Unlike most calcium antagonists and a-blockers the relationship is not linear but of a nonlinear saturable E max nature' 15 '. For most ACE inhibitors the doses used in clinical practice are on the upper linear plateau of the concentration effect curve. As a consequence it is possible to prolong the apparent drug effect by further increasing the dose. Whilst most ACE inhibitors may be given once-daily (if the dose is sufficiently high), the optimal regimen for some ACE inhibitors may be twice-daily at a greatly reduced daily dose" 6 '. influenced if their formation or degradation involves a neutral carboxypeptide. Such peptides include substance P, enkephalins and luteinizing hormone releasing hormone. Individual ACE inhibitor molecules can have additional properties which could be of therapeutic relevance. Such properties may include non-enzymeinhibiting properties such as free radical scavenging potential as discussed above for SH-containing compounds' 4 '.
Pharmacodynamic differences
Other molecules have been identified and are in clinical development which possess not only ACE inhibiting properties but also neutral endopeptidase inhibition'
171 . This latter effect will impair the breakdown of natriuretic peptides and potentiate the vasodilating and 
Clinical relevant differences in hypertension
As far as anti-hypertensive efficacy is concerned it appears that all clinically available ACE inhibitors lower blood pressure if given in an appropriate dose to patients with essential hypertension 1 '
1
. There are well recognized differences between the time course of onset of maximum effect, offset and duration of action. Thus the optimal dose and dose frequency/dose interval may vary from three times daily to once-daily [l21 . At present there is no convincing data comparing ACE inhibitors suggesting clinically relevant differences in anti-hypertensive efficacy. Similarly, although there is evidence that ACE inhibitors will reverse left ventricular hypertrophy and reduce proteinuria, there is no compelling evidence of difference between drugs if an appropriate regimen is employed. As far as 'hard' end-points of morbidity and mortality are concerned, there are not only no comparative data, but at present there is no prospective clinical trial evidence at all with respect to this class of drugs.
Side effects may reveal more consistent and potentially relevant differences. Early reports of taste disturbance (dysgeusia) suggested this was more common with captopril and has been attributed to the presence of an SH group' 5 '. Cough as a side effect appears to be related to bradykinin or other nonangiotensin mechanism as cough is not a feature of angiotensin II receptor antagonists 1 
Clinically relevant differences in heart failure
The objectives of treatment of heart failure with ACE inhibitors differ from those in hypertension. In the latter group blood pressure presents a readily measurable marker of drug effect to which a quantitative 'target' can be applied. Blood pressure as an intermediate phenotype for cardiovascular outcome can be used to monitor response to treatment and adherence to an optimal regimen. In contrast, in heart failure there is no such simple quantitative index and there remain doubts and difficulty about determining the optimal dose and dose frequency. The therapeutic objective of ACE inhibition in heart failure is to prevent progression of left ventricular dysfunction and ultimately to delay or arrest progression of heart failure and death' 2 '. Several ACE inhibitors with differing kinetic profiles have been confirmed to achieve these objectives' 2 '. This increasingly suggests that the improvement in outcome in heart failure is a class effect of ACE inhibitors. There is no information on comparative studies of the effects of different ACE inhibitors on outcome. However, subgroup analysis of some of the large trials suggest that early haemodynamic changes, particularly early hypotension in the CONSENSUS II Study may be associated with a less good outcome than patients without hypotension' 2 ''. This could be of clinical importance to the choice of ACE inhibitor in heart failure as the best documented differences between ACE inhibitors are in the time course and intensity of the early blood pressure changes after the first dose [22) . In three placebo-controlled parallel group studies of blood pressure changes after initiation of anti-hypertensive treatment we have observed characteristic and consistent patterns of blood pressure fall' 23 " 251 .
Captopril caused an early short-lived fall, enalapril led to a delayed but long-lasting fall, while perindopril in two studies did not alter blood pressure differently to placebo over the first 24 h (Fig. 2) . These findings have been subsequently confirmed in a similar study in another centre 1261 . There could be advantages in initiating treatment with the ACE inhibitor least likely to cause early hypotension.
